Intravenous pulsed vs oral cyclophosphamide therapy in steroid dependent nephrotic syndrome

S Abeyagunawardena¹, A H H M Jayaweera², R S Thalgahagoda², U I Karunadasa², *A S Abeyagunawardena²


Abstract

Background: No consensus exists concerning dose and route of administration of cyclophosphamide (CYC) in steroid-dependant nephrotic syndrome (SDNS).

Objective: To compare the outcome of children with SDNS treated with either intravenous (IV) or oral CYC in a single centre in Sri Lanka by reviewing data from 2002 to 2011.

Method: One hundred and twenty seven children with SDNS with evidence of steroid toxicity received either oral or IV cyclophosphamide. Seventy two received IV cyclophosphamide in a dose of 500 mg/m² monthly for 6 months, and 55 received oral CYC in a dose of 3 mg/kg per day for 8 weeks. In both groups prednisolone was tapered over 6 months in a similar manner. Full blood counts were done weekly during oral treatment and monthly during IV treatment. Patient progress was assessed on a monthly basis for the first year and at 3 monthly intervals thereafter till 5 years.

Results: In the oral CYC group, 4 patients developed bone marrow suppression, 7 had serious infections, 15 had significant alopecia and one child died due to overwhelming sepsis. In the IV group alopecia was seen in 9 patients and one had a serious infection while bone marrow suppression was not seen. At one and 5 year follow ups there was no significant difference in the proportion who suffered a relapse in the 2 groups (p >0.05)

Conclusion: In SDNS, IV cyclophosphamide was as effective as oral CYC in inducing sustained remission and had less side effects and a smaller total dose.

¹Teaching Hospital Peradeniya, Sri Lanka; ²Faculty of Medicine, University of Peradeniya, Sri Lanka
*Correspondence: asiriabey26@gmail.com

(Received on 04 January 2017: Accepted after revision on 17 February 2017)

The authors declare that there are no conflicts of interest

Personal funding was used for the project.

Open Access Article published under the Creative Commons Attribution CC-BY License

DOI: http://dx.doi.org/10.4038/sljch.v46i4.8377

(Keywords: Oral cyclophosphamide, intravenous pulsed cyclophosphamide, childhood steroid dependent nephrotic syndrome)

Introduction

Nephrotic syndrome (NS) has an annual incidence of 2-7 per 100,000¹. It describes the triad of generalised oedema, heavy proteinuria and hypoalbuminaemia². In about 90% of cases it is a primary glomerular disease. The remainder is caused by systemic disorders like systemic lupus erythematosus, vasculitis, infections, drugs and heavy metals³. The peak age of presentation of NS is 2 years, 70-80% cases occurring in children below 6 years⁴. NS can be classified into secondary, congenital, and idiopathic with idiopathic NS being the most frequent form in children⁵. Approximately 80% of primary NS patients have minimal change disease histologically. More than 90% respond to corticosteroid therapy and have a good long term prognosis⁶. Over 70% of these patients subsequently develop relapses and more than 50% will progress to frequently relapsing nephrotic syndrome (FRNS) or steroid dependent nephrotic syndrome (SDNS). The majority will eventually enter long term remission without progression to end stage renal disease⁷,⁸. Steroid dependency is defined by the International Study for Kidney Diseases in Children as children with FRNS in whom two consecutive relapses, or two of four relapses in any 6 month period, occurred while still on a steroid dose or within 14 days of stopping steroid therapy⁹. Relapses are associated with many acute complications like infections, hypovolaemia, thromboembolism and hypertension¹⁰. Children with FRNS and SDNS become vulnerable for these complications repeatedly. Each relapse is treated with induction of remission with prednisolone 60mg/m² as a single daily dose until remission, followed by 40mg/m² every other day for 28 days¹¹. Frequent relapses and steroid dependency exposes these children to multiple courses of high-dose prednisolone placing them at risk of a plethora of significant corticosteroid related side-effects such as hypothalamic-pituitary-adrenal axis suppression, hypertension, Cushing syndrome, obesity, bone disease, growth retardation, posterior lenticular cataracts, pubertal delay and behavioural disturbances¹²,¹³,¹⁴.
Present guidelines recommend that the first line of treatment for FRNS and SDNS is maintenance therapy with low dose prednisolone 0.1-0.6mg/kg on alternate days for a period of 6 months followed by slow tapering. Repeated courses of high dose daily steroids can cause more toxicity than these alternate day regimes. If the prednisolone dose required to maintain stable remission is more than 0.6mg/kg every other day or if the child develops steroid toxicity, steroid sparing immunosuppressive agents are introduced.

The only immunosuppressive agents which have been demonstrated by randomised controlled trials (RCT) to be effective in maintaining stable remission in FRNS and SDNS are immunomodulating agents (levamisole), alkylating agents (cyclophosphamide, chlorambucil) and calcineurin inhibitors (cyclosporine). The present practice is to use levamisole followed by alkylating agents first and reserve cyclosporine for patients who relapse frequently while on these agents. Both alkylating agents have been demonstrated to induce a prolonged period of stable remission after discontinuation of the drug whereas both levamisole and cyclosporine are known to result in relapse after cessation of therapy. Of the two alkylating agents which show similar efficacies, cyclophosphamide (CYC) is the most widely used due to its lower toxicity profile. However, no consensus exists concerning dose and route of administration of CYC in SDNS.

**Objective**

To compare the outcome of children with SDNS treated with either intravenous (IV) or oral CYC in a single centre in Sri Lanka by reviewing data from 2002 to 2011.

**Method**

The Professorial Paediatric Unit of the Teaching Hospital Peradeniya is a tertiary referral centre to which most patients with complicated NS are referred. Clinical data of all patients with NS were entered and regularly updated on a computerised database since 2002 in accordance with the data protection act 1998 and patient confidentiality and the approval of the Research and Ethics Committee of the Faculty of Medicine, University of Peradeniya. This database was maintained throughout by the principal author.

When a patient relapsed more than twice while receiving prednisolone above 1 mg/kg on alternate days with or without levamisole or when unacceptable side effects were encountered with alternate-day prednisolone and levamisole therapy, they were considered for CYC therapy. The decision to administer oral or IV was made after discussing with parents regarding the potential advantages and disadvantages. The distance to the local healthcare facility and the potential to default treatment due to social circumstances were also taken into consideration.

All such patients considered for CYC therapy received an identical steroid regimen irrespective of the route of administration. The induction of remission was achieved with oral prednisolone prescribed in a dose of 60mg/m² daily till remission followed by 40mg/m² every other day for 4 weeks and the steroid therapy was tapered over the next four months.

**Oral route**

Once the patient entered remission with daily prednisolone, CYC was prescribed orally 3mg/kg as a single dose for eight weeks. During oral therapy patients were reviewed and full blood counts were performed weekly focusing on potential side effects and relapse of proteinuria. After completion of CYC therapy patients were reviewed on a monthly basis for the first one year and thereafter at 3 monthly intervals.

**Intravenous route**

Intravenous pulses of CYC were administered at monthly intervals at 500mg/m² and were reviewed monthly to monitor for potential side effects and relapse of proteinuria. Thereafter all patients were closely monitored at the renal clinic for first one year with monthly reviews and 3 monthly reviews for the following years.

All parents were trained to test for early morning samples for urine protein excretion by sulphasalicylic acid test and were advised to record it on a daily basis in the patient held record book provided. Urine protein excretion of ++ or more for 3 consecutive days was diagnosed as a relapse.

Patients who had completed 5 years of follow up were included in the study. Patients who were lost to follow up and patients who had a renal histology other than minimal change disease were not considered for analysis. Patients who have had other immune suppressive therapy such as cyclosporine A or mycofenolate mofetil prior to CYC therapy were also excluded. The data of patients were obtained from the database and were analysed for this study using SPSS software version 19.

**Results**

One hundred and twenty seven children with SDNS with evidence of steroid toxicity who satisfied the entry criteria during the 10 year period received either oral CYC (55) or intravenous CYC (72). Six other patients were not considered as they were lost to follow up (4 IV route and 2 oral route). Results are summarised in Table 1.
Table 1: Summary of results (n=127)

<table>
<thead>
<tr>
<th></th>
<th>Oral cyclophosphamide therapy (n=55)</th>
<th>IV cyclophosphamide therapy (n=72)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males</td>
<td>34</td>
<td>49</td>
</tr>
<tr>
<td>Females</td>
<td>21</td>
<td>23</td>
</tr>
<tr>
<td>Dose</td>
<td>3 mg/kg per day</td>
<td>500 mg/m² monthly</td>
</tr>
<tr>
<td>Duration</td>
<td>8 weeks</td>
<td>6 months</td>
</tr>
<tr>
<td>Mean total dosage (mg/kg)</td>
<td>168</td>
<td>128 (range 110-134)</td>
</tr>
<tr>
<td>Age range at prescription (years)</td>
<td>2.6–14.2</td>
<td>2.3-13.5</td>
</tr>
<tr>
<td>Median age (years)</td>
<td>8.8</td>
<td>9.5</td>
</tr>
<tr>
<td>Side-effects/ complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone marrow suppression</td>
<td>04</td>
<td>0</td>
</tr>
<tr>
<td>Serious infections</td>
<td>07</td>
<td>01</td>
</tr>
<tr>
<td>Alopecia</td>
<td>15</td>
<td>09</td>
</tr>
<tr>
<td>Death</td>
<td>01</td>
<td>0</td>
</tr>
<tr>
<td>Number of patients who relapsed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 1 year of follow up</td>
<td>22 (40.0%)</td>
<td>28 (38.9%)</td>
</tr>
<tr>
<td>At 5 year of follow up</td>
<td>42 (76.4%)</td>
<td>53 (73.6%)</td>
</tr>
<tr>
<td>Sustained remission</td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 1 year</td>
<td>33 (60.0%)</td>
<td>44 (61.1%)</td>
</tr>
<tr>
<td>At 5 years</td>
<td>13 (23.6%)</td>
<td>19 (26.4%)</td>
</tr>
</tbody>
</table>

One child died in the oral CYC group due to overwhelming sepsis. At one year of follow up there were no significant differences in the numbers who relapsed in the oral and CYC groups (p>0.05 comparison of 2 proportions using Standard Error). Similarly, at 5 years of follow up there were no significant differences in the numbers who relapsed in the oral and CYC groups (p >0.05)

Discussion

SDNS is a challenge to the clinician who has to deal with not only the disease and its acute complications but also with the plethora of side effects associated with the treatment that has to be offered. As most children eventually outgrow the disease, balancing benefits of various cytotoxic agents against the risks is a matter of considerable importance. Thus, treatment of children with FRNS and SDNS needs to be individualised.

CYC was introduced as a steroid-sparing agent in 1967. It exerts its immunosuppressive effect by binding to purine bases and impairing normal DNA transcription. The beneficial effect of CYC in maintaining stable remission even after ceasing therapy in SDNS is well established by randomised controlled trials.

However, like all cytotoxic medications, CYC gives rise to several adverse effects causing long term morbidity. Short term side effects include haemorrhagic cystitis, leucopenia, infections and temporary alopecia and the long term side effects include gonadal toxicity and greater risk of malignancy. The risk of gonadal toxicity is more commonly seen in boys and increases if CYC is administered during the peri-pubertal period. Low sperm counts and future risk of malignancies are related to a cumulative dose exceeding 300mg/kg.

The best way to administer CYC minimising the potentially harmful side effects while maintaining its therapeutic benefits is yet to be established. Current practice is to give oral CYC 3mg/kg/day as a single dose for 8 weeks along with a tapering course of alternate day prednisolone which can be discontinued. The cumulative dose of oral course comes to 168mg/kg. A second course of CYC can be given after a period of one year if children continue to relapse. Over 80% of patients remained in long-term remission after a second course, off all treatment or on low-dose every other day prednisolone in one study. This would come to a cumulative dose of 336mg/kg which exceeds the safe range of 300mg/kg.

This study reveals that there is no difference in terms of efficacy in maintaining sustained remission between intravenous CYC and oral CYC in SDNS. However, the serious side effects often associated with CYC were not observed in the group treated IV compared to the group treated orally with CYC.

Furthermore, the cumulative dose of the oral course is 168mg/kg and that of the IV course remained between 110–134mg/kg. This would allow a second course to be repeated if necessary via the IV route while maintaining the cumulative dose below the toxic threshold of 300mg/kg. Moreover, intravenous therapy is more reliable when considering non-compliant patients.
Conclusions
In SDNS, IV cyclophosphamide was as effective as oral CYC in inducing sustained remission and had less side effects and a smaller total dose.

References

2. British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians. Consensus statement on management and audit potential for steroid responsive nephrotic syndrome. Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians. Archives of Disease in Childhood. 1994; 70(2):151-7. https://doi.org/10.1136/adc.70.2.151 PMid: 8129444 PMCid: PMC1029725


